11.10.2018 – BIOSPAIN 2018 registers an 11% increase in the number of business meetings held

 In notas de prensa
  • Figures from the ninth edition of BIOSPAIN solidify this event’s position as the largest country-based event in Europe;
  • No previous edition had managed to gather as many investors in life sciences (54), which demonstrates this group’s growing interest in Spanish biotechnology;
  • 26% of attendees came from overseas.

 

Madrid, 11 October 2018. The Spanish Bioindustry Association (ASEBIO) and the Regional Government of Andalusia organised the biennial event BIOSPAIN at Seville’s FIBES Exhibition & Congress Centre between 25 and 27 September. BIOSPAIN has become a great platform for the international visibility of Spanish biotechnology, consolidating its position as the largest country-based biotech event in Europe.

To organise the event, a steering committee was created, led by ASEBIO and the Innovation and Development Agency of Andalusia (IDEA), and with the direct participation of the Regional Ministry of Agriculture, Rural Development and Fisheries, the Andalusian Knowledge Agency and the Progress and Health Foundation representing their ministries (Knowledge, Research and University; Health; and Employment, Enterprise and Commerce).

This edition has shown that BIOSPAIN is an event that not only consolidates figures but also increases them compared to previous years. In fact, in this ninth edition, there were 3,330 partnering meetings or business meetings, which shows an 11% increase with respect to the previous edition. In addition, the number of investors attending the congress increased to 54, which shows that more and more professionals are interested in seeking investment opportunities in our country.

BIOSPAIN is a platform for attracting international investors, as evidenced by the fact that investors who have committed to life sciences projects in Spain attended this event.

For example, in 2014, Forbion, Edmond de Rothchild, Ysios Capital Partners, La Caixa and Novartis attended the event’s investor forum, and in that same year Sanifit, Palobiofarma, Minoryx and Medlumics presented their projects. In addition, Minoryx and Medlumics also presented projects in 2012, the year that the majority of the aforementioned investors attended.

In this edition, Philippe Monteyne, partner of Fund+, who gave a plenary conference, announced at BIOSPAIN on 27 September that they had participated, along with Ysios Capital Partners, in the round of financing for Minoryx, amounting to 21 million Euros. This is the largest round involving a Spanish biotech company so far this year.

At BIOSPAIN investors had the opportunity to listen to up to 40 projects from Spanish (32) and international companies, which can be viewed using the following links:

 

https://biospain2018.org/program/#event-80

https://biospain2018.org/program/#event-104

https://biospain2018.org/program/#event-1586

https://biospain2018.org/program/#event-1587

 

ATTENDANCE FIGURES

On the other hand, in terms of attendance there were 1,550 delegates, 773 companies, of which 26% were international (from 30 countries), and 200 exhibitors.

In the attendee survey, which is carried out after the event, 84% of respondents answered that they identified real business opportunities. The event was rated as good or very good by 92.3% of attendees.

Jordi Marti, President of ASEBIO, believes that “BIOSPAIN is not only a reference event for consolidated sectors working with biotech entities, but also for public institutions. The attendance of Susana Diaz, President of the Regional Government of Andalusia, along with other relevant people from the regional government, shows biotechnology’s importance for Andalusia. Furthermore, the presence of 54 investors is a clear example of the fact that in Spain there are quality projects worth coming to see.”

In the opinion of Julio Coca, General Director of IDEA, “Biotechnology is a strategic productive sector in Andalusia, since it is the first autonomous community in the creation of new biotech companies, the second in the number of companies that use biotechnology, and the third in companies whose main activity is biotechnology. In this context, BIOSPAIN is a key component for this sector. Following the success of this 2018 edition, it only remains for us to thank ASEBIO for the magnificent work they did and once again offer Andalusia as the venue for future editions, and offer all our collaboration to keep repeating and increasing these fantastic results”.

This year’s BIOSPAIN programme gave dedicated space to biomedicine, although a good part of the programme was also dedicated to agri-food and industrial biotechnology, mainly in the field of the bioeconomy. The sessions focused on financing also had a noticeable presence. Among the main topics addressed in this ninth edition, the following stand out: Alzheimer’s disease, advanced therapies, agri-food, biobanks, funding programmes, the circular economy, artificial intelligence, gene editing, immunotherapy, resistance to antibiotics, precision medicine, etc.

 

For more information:

Lucía Cecilia

Director of Communications for ASEBIO and BIOSPAIN 2018

Tel. + 34 912109374/10

Mobile: + 34 663 117 293

e-mail: lcecilia@asebio.com

www.asebio.com

 

Press office:

Berbés Asociados – Tel. + 34 91 563 23 00

María González / + 34 677 456 806

e-mail: mariagonzalez@berbes.com

 

Recent Posts

Leave a Comment

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here, or follow this link for more information about cookies.

ACEPTAR
Aviso de cookies